AstraZeneca (Pfizer Bid) Debate

Full Debate: Read Full Debate
Tuesday 6th May 2014

(10 years ago)

Commons Chamber
Read Full debate Read Hansard Text

Urgent Questions are proposed each morning by backbench MPs, and up to two may be selected each day by the Speaker. Chosen Urgent Questions are announced 30 minutes before Parliament sits each day.

Each Urgent Question requires a Government Minister to give a response on the debate topic.

This information is provided by Parallel Parliament and does not comprise part of the offical record

Vince Cable Portrait Vince Cable
- Hansard - - - Excerpts

As I have already said, I would certainly rule out intervention on protectionist grounds, but I am not ruling out intervention, because we need to look at all the options available to us.

Pat McFadden Portrait Mr Pat McFadden (Wolverhampton South East) (Lab)
- Hansard - -

I agree with the Secretary of State when he says that this issue should not be decided on the basis of whether the proposed takeover comes from a foreign company. There is enough narrow nationalism in British politics without our adding to it here. However, there is a question of whether companies keep their promises. The right hon. Gentleman has referred several times to Kraft and Cadbury. Kraft broke its word when it said that it would keep open the Somerdale factory and then announced, after the bid had gone through, that it was going to close it. The question now is how does the right hon. Gentleman know and how can he ensure that, if the takeover goes through, Pfizer will keep its promises on R and D and the British science base?

Vince Cable Portrait Vince Cable
- Hansard - - - Excerpts

Should this proceed—as I said at the outset, we have not yet had a formal bid—it will obviously be a matter for negotiation. I am sure that the right hon. Gentleman would not want me to go into exactly what is being said in the discussions at the moment. Negotiations will clearly happen to make sure that any obligation is binding. I am sure that Pfizer itself would want to ensure that any obligations are clear and binding. Just to reinforce the point about nationality, which the right hon. Gentleman rightly stressed at the outset, we are talking about two international companies. I think we all acknowledge that AstraZeneca is an admirable company. It is Anglo-Swedish, with a Swedish chairman, a French chief executive and an international shareholder base. Pfizer is predominantly an American company and has a British chief executive. We are talking about international companies.